The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.
Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.
Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.
The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.
To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market
Further key findings from the report suggest:
Incidence of ovarian cancer worldwide has been declining over the past decades
Although ultrasound imaging is the fist-line of diagnosis, the technique cannot be used for staging the disease
Computerized Tomography (CT) imaging is preferred for staging the disease
CA125 remained the mainstay in blood test biomarkers in 2018
HER2 and BRCA1/2 tests are expected to witness a rapid growth during the forecast period owing to the rising awareness of early diagnosis and genetic tests
The ovarian cancer diagnostics market in Asia Pacific is expected to grow at a high rate during the forecast period.
Grand View Research has segmented the global ovarian cancer diagnostics market on the basis of cancer type, diagnosis type, end use, and region:
Ovarian Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2015 - 2026)
Epithelial Tumor
Germ Cell Tumor
Stromal Cell Tumor
Others
Ovarian Cancer Diagnostics Diagnosis Type Outlook (Revenue, USD Million, 2015 - 2026)
Imaging
Ultrasound
CT Scan
MRI Scan
PET Scan
Others
Blood Test
CA125
HER2
BRCA
CEA
ER & PR
KRAS Mutation
Others
Biopsy
Others
Ovarian Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2015 - 2026)
Hospital Laboratories
Cancer Diagnostic Centers
Research Institutes
Others
Ovarian Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
UAE
Saudi Arabia
Explore Horizon, the world’s most expansive market research database
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Sign in to leave a comment.